title: Are clinical laboratories in California accurately reporting vancomycin-resistant enterococci?
abstract: In order to determine whether hospital-based clinical laboratories conducting active surveillance for vancomycin-resistant enterococci in three San Francisco Bay area counties (San Francisco, Alameda, and Contra Costa counties) were accurately reporting vancomycin resistance, five vancomycin-resistant enterococcal strains and one vancomycin-susceptible beta-lactamase-producing enterococcus were sent to 31 of 32 (97%) laboratories conducting surveillance. Each strain was tested by the laboratory's routine antimicrobial susceptibility testing method. An Enterococcus faecium strain with high-level resistance to vancomycin (MIC, 512 microg/ml) was correctly reported as resistant by 100% of laboratories; an E. faecium strain with moderate-level resistance (MIC, 64 microg/ml) was correctly reported as resistant by 91% of laboratories; two Enterococcus faecalis strains with low-level resistance (MICs, 32 microg/ml) were correctly reported as resistant by 97 and 56% of laboratories, respectively. An Enterococcus gallinarum strain with intrinsic low-level resistance (MIC, 8 microg/ml) was correctly reported as intermediate by 50% of laboratories. A beta-lactamase-producing E. faecalis isolate was correctly identified as susceptible to vancomycin by 100% of laboratories and as resistant to penicillin and ampicillin by 68 and 44% of laboratories, respectively; all 23 (74%) laboratories that tested for beta-lactamase recognized that it was a beta-lactamase producer. This survey indicated that for clinically significant enterococcal isolates, laboratories in the San Francisco Bay area have problems in detecting low- to moderate-level but not high-level vancomycin resistance. Increasing accuracy of detection and prompt reporting of these isolates and investigation of cases are the next steps in the battle for control of the spread of vancomycin resistance.
authors.affiliation: Division of Communicable Disease Control, California Department of Health Services, Berkeley 94704, USA. jrosenbe@hwl.cahwnet.gov
authors.forename: J
authors.initials: J
authors.lastname: Rosenberg
authors.forename: F C
authors.initials: FC
authors.lastname: Tenover
authors.forename: J
authors.initials: J
authors.lastname: Wong
authors.forename: W
authors.initials: W
authors.lastname: Jarvis
authors.forename: D J
authors.initials: DJ
authors.lastname: Vugia
mesh_terms: D000667:Ampicillin / Q000494:pharmacology; D002140:California / Q000453:epidemiology; D018563:Disease Notification; D004352:Drug Resistance, Microbial; D016983:Enterococcus / Q000187:drug effects*; D016908:Gram-Positive Bacterial Infections / Q000453:epidemiology; D006801:Humans; D007753:Laboratories; D008826:Microbial Sensitivity Tests / Q000379:methods; D015588:Observer Variation; D010406:Penicillins / Q000494:pharmacology; D011159:Population Surveillance; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D014640:Vancomycin / Q000494:pharmacology*
chemical_list: D010406:Penicillins; D014640:Vancomycin; D000667:Ampicillin